Order expected to affect specific medications covered under Medicare that are administered in a health care setting.

SGLT2 inhibitors may enable continuation of RAAS inhibitors for hypertension treatment, which is linked with better kidney and cardiovascular outcomes.

The prophylactic efficacy of TMP-SMX was significantly higher in subgroups with baseline lymphopenia, azotemia, microscopic polyangiitis, or relapsed AAV.

Geographic disparities seen, with greater percentage of cardiovascular deaths attributable to di-2-ethylhexylphthalate exposure for South Asia, Middle East.

(HealthDay News) — The number of kidney transplants performed annually in the United States has increased steadily, but with decreasing allocation efficiency, according to a study published online in ...

Sustainable development efforts such as lowering out-of-pocket health expenses can reduce future prevalence of AMR by 5.1 percent.

Patients with DME who are treated using aflibercept are more likely to experience acute kidney injury or hospitalisation due to renal events than those treated with ranibizumab. Using a target ...